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in contrast to fixation at pressures of at least 2 mm Hg,
has been shown to preserve nearly normal extensibility
of the leaflet collagen, which allows the leaflet to open
fully without kinking.1 This characteristic is expected to
increase postimplantation durability. Toluidine blue has
been employed as an anticalcification agent.
This device was released for clinical use by Xenotech
Inc (Irvine, Calif) in 1983 and was first implanted at
Green Lane Hospital in August of that year. Since then the
valve, renamed the Intact by Medtronic in 1986, has been
used by us for patients in whom a stent-mounted porcine
valve was considered preferable to other devices. We have
published 3 previous follow-up reports, with the most
recent an 8-year review.2-4 Since then the database has
been enlarged to include patients operated on until the end
of 1996.
T he Medtronic Intact valve (Medtronic, Inc,Minneapolis, Minn) is a porcine valve that is fixed
in glutaraldehyde at zero pressure and mounted on a
flexible acetyl copolymer stent. Zero-pressure fixation,
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Patients and methods
Study group. Between 1983 and the end of 1996, 447
patients (280 men and 167 women) received 466 Intact
valves. There were 9 multiple Intact valve replacements, and
10 patients received a second Intact valve at reoperation.
These 10 were reentered into the data set at that time. The
total number of operations was 456.
Two hundred eighty valves were inserted in the aortic posi-
tion, 156 were inserted in the mitral position, and 30 were
inserted in the tricuspid position. The valve sizes are shown
in Table I. Valve distribution by patient age at implantation
and position is given in Table II, and the mean, median, and
range of ages are shown in Table III. Only 55% were older
than 60 years. Patients undergoing aortic replacement were
older than mitral and tricuspid valve recipients (P = .0001).
Most younger patients were either New Zealand Maoris or
Polynesians thought unlikely to be reliable in taking antico-
agulants or Polynesians returning to remote Pacific islands
where anticoagulant control was not possible. These ethnic
groups comprised 31% of the patients and 71% of those
younger than 40 years.
Twelve patients were in New York Heart Association
(NYHA) class I, 87 were in class II, 207 were in class III, 138
were in class IV, and 12 were in class V (unable to leave bed
or undergoing emergency operations). The mean NYHA class
was 3.1.
The procedure involved a first operation with a single valve
replacement in 65% of patients. Previous valve operations
had been undertaken in 18% of patients and concurrent oper-
ations (coronary artery bypass grafting or resection of
ascending aortic arch aneurysm or left ventricular aneurysm)
were performed in 33% of patients. Concurrent replacement
or repair of another valve was undertaken in 20%. The addi-
tional valve replacement was an Intact in 9 cases, an aortic
homograft in 39 cases (making a total tissue valve replace-
ment), and a prosthetic valve in 14 cases. The Intact valve
was confined to the tricuspid position in all but 1 of the last
group of patients.
Management. The valves were inserted by 8 different sur-
geons, usually with interrupted sutures. All patients received
antibiotic prophylaxis given immediately before and usually
for 3 days after operation. Routine warfarin anticoagulation
was started on the second postoperative day and discontinued
after 6 weeks, except when there was chronic atrial fibrilla-
tion or a prosthetic valve in another site, in which case it was
permanent. The aim was to maintain the international nor-
malized ratio between 2 and 3.
Follow-up. Follow-up was undertaken during the second
half of 1996 and was 98% complete. It extended for a mean
of 39 (1-154) months, corresponding to 1324 patient-years.
Patients with a shorter follow-up than 3 years were
reviewed by their general practitioners unless symptoms were
present, in which case they were seen by a cardiologist. Most
of those with follow-up beyond 3 years were seen by a cardi-
ologist, and echocardiography was performed whenever pos-
sible. All videotapes were reviewed by 1 of us (W.M.J.) with-
out knowledge of the patient’s clinical status.
A Sonos 2000 Doppler echocardiographic unit (Hewlett
Packard Company, Andover, Mass) was used. Multiple win-
dows were used to record aortic velocity. Left ventricular out-
flow velocity was measured with pulsed-wave Doppler ultra-
sonography. Mean mitral and aortic gradients were calculated
by planimetry of 3 waveforms for patients in sinus rhythm
and of 10 waveforms if atrial fibrillation was present. The
mean aortic gradient was corrected for the left ventricular
outflow gradient. The equation of continuity was used to cal-
culate aortic valve area. Mitral valve area was calculated by
the pressure half time method. The presence of regurgitation
was assessed by color flow imaging.
Data analysis. Patient survival and other events were ana-
lyzed with Kaplan-Meier actuarial curves, and comparisons
were made with the Mantel-Haenszel log-rank test. These
curves are presented at 10 years of follow-up, because
beyond that time the numbers at risk were too small to be sig-
nificant. Because only 9 patients had more than 1 Intact
valve, a multivalve category was not included except in the
case of patient survival, in which the multivalve category
included patients with replacement of more than 1 valve
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Table I. Valve use by position
Valve position
Valve size (mm) Aortic Mitral Tricuspid
23 76 0 0
25 96 0 0
27 65 5 0
29 42 27 2
31 0 71 7
33 0 48 17
35 1 5 4
Total 280 156 30
Table II. Valve distribution by age and site
Total
Decade Aortic Mitral Tricuspid No. %
10-19 y 2 10 3 15 3
20-39 y 25 38 8 71 15
40-59 y 62 50 10 122 26
60-82 y 191 58 9 258 55
Total 280 156 30 466
Table III. Age in years at operation
Valve site Mean Range Median
Aortic (n = 280) 63 19-82 68
Mitral (n = 156) 50 12-78 53
Tricuspid (n = 30) 46 11-73 46
Total (n = 466) 57 11-82 63
regardless of the type of device. For events other than survival
the analysis considered the 466 valves rather than the 447
patients. The 2-tailed Fisher exact test was used for compar-
isons of categoric data.
Results
Survival. The 30-day mortality rate was 8.9% (40
patients). The risk increased with age increment in dou-
ble decades (P = .004), and there was a nonsignificant
trend toward higher mortality rates among patients
undergoing associated coronary artery bypass grafting
or double valve replacement. There were 5 deaths
among the 13 patients in NYHA class V (38%).
There were 92 subsequent deaths (20%), all but 4 of
which occurred within 10 years of operation. Autopsy
was performed in only 9 cases. The probable causes of
death are listed in Table IV. The designation sudden
death includes death during sleep and from known
arrhythmia. Although some of these may have been
embolic in origin, none is included under the category
of thromboembolism because most were probably from
arrhythmia. Before the operation, 15 of the 21 patients
with sudden deaths had severe aortic valve disease,
associated in 11 cases with severe left ventricular
hypertrophy. Nine patients were assumed to have
thromboembolic stroke and 2 others were assumed to
have hemorrhagic stroke in association with an ex-
tremely elevated international normalized ratio (none
underwent a brain scan). Eighteen of these late deaths
can be considered to be related to the study valve (9
from thromboembolism, 5 from infective endocarditis,
and 4 from anticoagulant-related hemorrhage). In addi-
tion, pathologic condition of the study valve may have
contributed to death in 3 cases of patients dying of
heart failure (perivalvular leakage in 1 case and mitral
stenosis in 2 cases).
Actuarial survival at 10 years was 30% ± 6%, com-
pared with an actuarial survival of 70% in a matched
general population (Fig 1). When in-hospital deaths
were excluded, the slope of the curve was similar to
that of the general population for the first 5 years but
then showed a more rapid decline. When noncardiac
deaths were excluded, survival was 41% ± 7%. There
was no significant difference in survival between
patients receiving isolated valve and multivalve
replacements, nor between patients undergoing isolat-
ed aortic and isolated mitral valve replacement, nor
between patients with or without coronary artery
bypass grafts. Survival among patients in NYHA class-
es IV and V was 14% ± 7%, compared with a survival
of 39% ± 8% among patients in classes I to III (P =
.001, Fig 1).
Infective endocarditis. Infective endocarditis
occurred on 13 Intact valves: 7 aortic, 5 mitral, and 1
tricuspid (in which the primary focus was on a left-
sided prosthetic valve). Six underwent reoperation,
with 2 deaths. The actuarial freedom from this event at
10 years was 92% ± 3%.
Thromboembolism, valve thrombosis, and antico-
agulant hemorrhage. Thirty-four patients were classi-
fied as having thromboembolism, including all those
with permanent and transient stroke. None of these
patients had a prosthetic valve at another site. The inci-
dences were similar between patients with aortic and
mitral valve replacement.
There was 1 example of thrombosis of an aortic
Intact valve; this was recognized 6 months after im-
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Table IV. Causes of death
Cause of death No. %
Congestive heart failure 16 17
Myocardial infarction 12 13
Infective endocarditis 6 7
Stroke 9 10
Sudden death/arrhythmia 21 23
Bleeding 4 4
Cancer 11 12
Miscellaneous noncardiac 11 12
Unknown 2 2
Total 92 100
Fig 1. Actuarial survival of all patients, those in different
NYHA classes, and a matched general population. The bars
represent ± 1 standard error (70% confidence limits).
plantation and the valve was successfully replaced. Full
hematologic studies demonstrated the presence of
lupus anticoagulant. The actuarial freedom from throm-
boembolism (including the 1 case of valve thrombosis)
was 80% ± 5% at 10 years (Fig 2).
There were 4 examples of anticoagulant-related
bleeding associated with a prolonged international nor-
malized ratio. All were fatal, 2 as a result of stroke.
Minor incidents of bleeding not necessitating hospital-
ization were not recorded.
Structural valve deterioration. There were 26 cases
of structural valve deterioration, with an actuarial free-
dom of 74% ± 6% at 10 years, at which time there were
32 valves at risk. The valve site, mechanism, and patient
age are detailed in Table V. Most (17) were due to dif-
fuse leaflet calcification, usually producing pure steno-
sis but occasionally with tearing in the commissural
region and incompetence. In all but 3 instances these
patients were younger than 40 years. Calcification was
more common in the mitral position than in the aortic
position. Leaflet tearing without calcification was rare.
The most common cause of pure incompetence was but-
tress detachment (commissural dehiscence or stent post
dehiscence), which occurred in 5 mitral valves but in
only 1 aortic valve. This process involved detachment of
the aortic wall remnant of the valve from the polyethyl-
ene terephthalate fabric (Dacron) covering the stent post
as a result of tearing out of the sutures from the aortic
wall. It produced prolapse of the commissural region
and of the cusp free edge (Fig 3). Two posts were affect-
ed in 1 case. The earliest occurrence was at 75 months
after implantation, and occurrences were seen thereafter
at fairly regular intervals until 136 months. Actuarial
freedom from this event at 10 years in the mitral posi-
tion was 85% ± 7% (Fig 4). There was 1 example of
perforation through the muscular shelf at the base of the
right aortic leaflet; this was associated with hemolysis.
Actuarial freedom from structural valve deterioration
in the aortic position was 81% ± 9% at 10 years (Fig 5).
There was 1 event beyond 10 years in a 49-year-old
patient as a result of buttress detachment. There were 3
events in the 27 patients younger than 40 years, yielding
an actuarial freedom of 33% ± 26% at 7 years, and 1
event in patients older than 40 years, yielding an actuari-
al freedom of 92% ± 8% at 10 years (Fig 6, P = .0005).
Actuarial freedom from structural valve deterioration was
100% at 10 years in the 192 patients 60 years old or older.
In the mitral position actuarial freedom from structur-
al valve deterioration at 10 years was 65% ± 8% (Fig 5).
There was no significant difference between age groups
(Fig 7). The actuarial freedoms from structural valve
deterioration at 10 years were 50% ± 12% for patients
younger than 40 years and 76% ± 9% for those 40 years
old and older (P = .1). An additional 6 events occurred
beyond 10 years, 4 in patients 20 to 37 years old and 2
in patients 60 and 63 years old. Structural valve deteri-
oration was unrelated to valve size (P = .39).
In the tricuspid position the numbers were small, but
freedom from structural valve deterioration at 10 years
was 100% (Fig 5). There was 1 valve removed beyond
10 years for calcific stenosis; this was done at 127
months in a 31-year-old patient.
Nonstructural valve deterioration. The category of
nonstructural valve deterioration comprises 8 peri-
valvular leaks (5 mitral and 3 aortic) and an entrapment
of 1 pillar of a valve in the tricuspid position beneath a
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Fig 2. Actuarial freedom from thromboembolism and valve
thrombosis. The bars represent ± 1 standard error (70% con-
fidence limits). The dotted line indicates no further events.
The number at risk is shown.
Table V. Structural valve deterioration
Failure mode <20 y 20-39 y 40-59 y ‡ 60 y
Aortic position (No.) 2 25 62 191
Calcification 0 3 1 0
Buttress detachment 0 0 1 0
Mitral position (No.) 11 36 46 54
Calcification 3 7 0 2
Tear without 0 0 0 2
calcification
Buttress detachment 0 2 1 2
Perforation muscle 0 0 0 1
shelf
Tricuspid position (No.) 3 9 11 9
Calcification 0 1 0 0
Totals (No.) 3 (19%) 13 (19%) 3 (3%) 7(3%)
large trabeculation in the right ventricle, which pro-
duced leaflet thickening and incompetence. Freedom
from this event was 95% ± 2% at 10 years.
Explantation. Explantation was undertaken on 47
occasions (Table VI), with 3 in-hospital deaths (6.3%).
Five of the valves were functioning normally and were
replaced with a prosthetic device at the time of reoper-
ation for a nonstudy valve in the hope of avoiding fur-
ther reoperation. Freedom from this event at 10 years
was 64% ± 6%, excluding the 5 normal valves. Ex-
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Fig 3. Photographs of an Intact valve removed because of buttress detachment. Stent post viewed en face and
laterally.
Fig 4. Actuarial freedom from buttress detachment in the
mitral position. The bars represent ± 1 standard error (70%
confidence limits). The dotted lines indicate no further
events. The numbers at risk are shown.
Fig 5. Actuarial freedom from structural valve deterioration
(SVD) in the aortic, mitral, and tricuspid positions. The bars
represent ± 1 standard error (70% confidence limits). The
dotted lines indicate no further events. The numbers at risk
are shown. NS, Not significant.
plantation was more common in the mitral position
than in the aortic position (Fig 8).
Valve-related events. Actuarial freedom from all
valve related events at 10 years was 51% ± 6%. Actuarial
freedom from valve-related death was 88% ± 3% (Fig 9).
Echocardiography. Doppler echocardiographic
examination was requested for all patients with a fol-
low-up beyond 3 years. In fact, echocardiography was
consented to by only 63 (65%) of patients with aortic
Intact valves, 29 (41%) of those with mitral Intact
valves, and 2 (13%) of those with tricuspid Intact
valves at a mean of 8 years (4-11 years) years after
implantation. Because all patients with symptoms
accepted the necessity for this examination, however,
we are confident that no examples of severe study valve
lesions were omitted.
In the aortic position (Table VII) moderate leaflet
thickening with a mean pressure gradient of 30 mm Hg
and an effective orifice area of 1.0 cm2 was noted in a
single 69-year-old patient, who was in NYHA class II.
One other 69-year-old patient, who was in NYHA class
I, had moderate stenosis (gradient 40 mm Hg, effective
orifice area 1.0 cm2). There were no examples of severe
stenosis, significant leaflet calcification, or significant
aortic regurgitation.
In the mitral position (Table VII) there were 2 exam-
ples of moderate leaflet thickening, 1 associated with
stenosis and the other with moderate central regurgita-
tion. The patient with stenosis (gradient 10 mm Hg,
effective orifice area 0.81 cm2) also had moderate leaflet
calcification but remained in NYHA class I. The second
patient with moderate incompetence had a perivalvular
leak with normal leaflets and was also in NYHA class I.
The 5 patients with echocardiographic abnormali-
ties are not included in the actuarial analysis of valve
morbidity.
Symptom status. Among surviving patients at final
review, 192 were in NYHA class I, 46 were in class II,
10 were in class III, and 2 were in class IV (1 because
of severe angina and 1 with a tricuspid Intact valve
because of congestive heart failure). The mean NYHA
class was 1.3.
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Fig 6. Actuarial freedom from structural valve deterioration
(SVD) in the aortic position according to patient age older
than 40 years and older than 60 years at implantation. The
bars represent ± 1 standard error (70% confidence limits).
The dotted lines indicate no further events. The numbers at
risk are shown.
Fig 7. Actuarial freedom from structural valve deterioration
(SVD) in the mitral position according to patient age in
decades at implant. The bars represent ± 1 standard error
(70% confidence limits). The dotted lines indicate no further
events. The numbers at risk are shown. NS, Not significant.
Table VI. Explantation
Cause Aortic Mitral Tricuspid
Structural valve deterioration 5 20 1
Perivalvular leakage, etc 3 5 1
Infective endocarditis 3 2 1
Valve thrombosis 1 0 0
Normal 2 3 0
Totals 14 30 3
Discussion
This report provides information to 10 years after
implantation on stented porcine valves fixed in glu-
taraldehyde at zero pressure. The 32 valves at risk at 10
years provide sufficient data from which to draw tenta-
tive conclusions at this interval, particularly in the aor-
tic position and particularly with respect to age at
implantation.
Although zero-pressure fixation is the key factor that
differentiates the Intact valve from porcine bioprosthe-
ses fixed under pressure, a number of other design fac-
tors can affect the result in stented valves and thus
make comparisons between bioprostheses difficult. For
example, poor stent design that distorts the leaflets will
result in earlier failure. A valve that is fixed under pres-
sure, with the leaflets closed and the aorta distended, is
easier to mount inside a stent than is a zero-pressure
fixed valve. Moreover, the nondistended aortic root and
inflow anulus of zero-pressure fixed tissue downward-
ly sizes the valve slightly and produces crowding of tis-
sue and suboptimal leaflet motion.5 This can be over-
come by fixing the aortic root at a physiologic pressure
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Fig 8. Actuarial freedom from explantation, excluding 5 nor-
mal valves. The bars represent ± 1 standard error (70% con-
fidence limits). The dotted lines indicate no further events.
The numbers at risk are shown.
Fig 9. Actuarial freedom from valve-related events and valve-
related deaths. The bars represent ± 1 standard error (70%
confidence limits). The dotted lines indicate no further
events. The numbers at risk are shown.
Table VII. Echocardiographic data obtained 8 (4-11) years after implantation
Absent Trivial Mild Moderate Severe
Aortic position (N = 63)
Leaflet thickening 33 25 4 1 0
Leaflet calcification 48 9 4 0 0
Aortic regurgitation 51 13 10 0 0
Mean pressure gradient (mm Hg) 15.4 ± 7.7 (4.4-45.0)
Average effective orifice area (cm2) 1.74 ± 0.59 (1.0-3.7)
Mitral position (N = 29)
Leaflet thickening 12 14 1 2 0
Leaflet calcification 24 1 3 1 0
Mitral regurgitation 18 3 6 2 0
Mean pressure gradient (mm Hg) 4.3 ± 2.2 (1-11)
Average effective orifice area (cm2) 1.9 ± 0.58 (0.81-3.20)
in combination with zero-pressure fixation of the
leaflets, a technology that is now available in stented6
and nonstented porcine valves.7,8
There is no obvious explanation for the lower than
expected 10-year actuarial survival of 30%, nor for the
finding of similar mortality rates between patients with
isolated aortic and isolated mitral valve replacement
and between those with isolated valve and multiple
valve replacement. A multivariate analysis to assess the
numerous risk factors9 has not been done, nor would it
be of great value because left ventricular function has
not been assessed in most cases. In other studies of
stented and prosthetic valves, survival has not been
related to the type of replacement device10 and deaths
related to the study valve in this series were acceptably
low (actuarial freedom of 88% ± 3%).
Possible factors related to the low survival include the
significantly lower survival of a matched New Zealand
population compared with a matched US population,
the poor compliance of Maori and Polynesian patients
with postoperative supervision, and the long surgical
waiting lists at Green Lane Hospital, the result of inad-
equate state funding. This last has resulted in a situation
in which patients must have severe symptoms before
being accepted for their initial operation and is in
marked contrast to North American practice, in which
patients are accepted earlier in their course, before the
onset of significant left ventricular damage. It must also
be emphasized that NYHA functional class correlates
poorly with left ventricular function, the most important
risk factor, particularly in aortic valve disease.9
These data are similar to those from other reports of
stented porcine valve implants with respect to the inci-
dence of infective endocarditis, nonstructural valve
dysfunction, and thromboembolism. The single exam-
ple of valve thrombosis occurred in the presence of
lupus anticoagulant.11
Structural valve deterioration is the most important
parameter of durability. The failure mode was leaflet
calcification in 17 of the 26 valves. Only 3 of these 17
failures occurred in patients older than 40 years (Table
V), indicating a much higher incidence in the first 4
decades as would be expected12 but a low incidence in
both the 40- to 59-year and the 60-year and older age
groups. This suggests that the practice of confining the
use of bioprostheses to patients older than 65 to 70
years may no longer be appropriate when zero-pressure
fixed tissue is used, because zero-pressure fixation may
play an important part in the low incidence by creating
a softer leaflet that does not kink on opening.13 Any
additional preventive effect from toluidine blue impreg-
nation of the leaflet is uncertain.
An unexpected failure mode was buttress detach-
ment, which was more common in the higher closing
pressure mitral position. This phenomenon, which is
not age related, has been reported with stent-mounted
homografts,14,15 with the low-pressure fixed supra-
annular Carpentier-Edwards valve,16,17 and rarely with
high-pressure fixed valves.18 Factors predisposing
toward buttress detachment include excess thinning of
the aortic wall before mounting the valve on the stent,16
increased loading of the affected post because of mis-
match of valve and stent, inadequate suturing tech-
niques during mounting, and, possibly in the case of
the Intact valve, zero-pressure fixation of the aortic
wall. The hazard function of buttress detachment is
uncertain because of insufficient numbers, but it has
not produced significant valve incompetence from
leaflet prolapse before the seventh year of follow up. It
is characteristically associated with absence of host tis-
sue fibrous overgrowth onto the aorta at the top of the
post. This overgrowth is almost always present and
securely attaches the valve to the stent, preventing its
detachment.18
Neither in this series nor in the larger Canadian expe-
rience19 did early cusp tearing occur in the aortic posi-
tion. The most likely cause of this failure mode20 is
tearing of the soft leaflet by long, stiff suture ends pro-
truding from the sewing ring.21 Early cusp tearing
could also be due to leaflet abrasion against the Dacron
stent covering, particularly if the valve is too large for
the stent and the leaflet tissue is redundant as a result.
Proper quality control should avoid this.22
The incidence of structural valve deterioration is
strikingly low in the aortic position in patients older
than 40 years, with an actuarial freedom at 10 years of
92% (1 event from calcification in 253 valves).
Actuarial freedom at 10 years was 100% in patients
older than 60 years. These results are reinforced by
similar findings after 9 years in the Canadian experi-
ence.19 The incidence of structural valve deterioration
in the mitral position is no better than for other porcine
valve types and is affected unfavorably by buttress
detachment. This reflects the known poorer perfor-
mance of a semilunar valve in this position. Although it
is not statistically significant, it is interesting to note
that the structural valve deterioration rate was lowest in
the 40- to 59-year age group and that there was a free-
dom from deterioration of approximately 55% at 8
years in the 58 patients younger than 40 years.
The Doppler echocardiographic data obtained 8
years (4-11 years) after the operations confirm that
valves, particularly in the aortic position, are not dete-
riorating significantly during this time frame. The
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mean transvalvular gradient for sizes 23 to 27 mm of
15 ± 7.7 mm Hg compares favorably with that of 13 ±
3 mm Hg measured 4 years after implantation in these
Intact valves.3 Other studies indicate an acceptable gra-
dient even in 21-mm diameter valves.23 These gradients
are produced by relatively bulky inflow annular tissue
in association with the leaflet hinging a few millimeters
away from its point of attachment to the aortic wall.
Patient age is by far the strongest incremental risk
factor for structural valve deterioration,12,24 with
almost all series of tissue valves showing a much lower
incidence among elderly patients than among younger
patients. In making comparisons between the Intact
valve and other tissue valves, the most sensitive index
may be the age before which the structural valve dete-
rioration incidence increases significantly. In the aor-
tic position for the standard high-pressure fixed
Carpentier-Edwards and Hancock valves this would
appear to be approximately 70 years,12,25 and for the
low-pressure fixed supra-annular Carpentier-Edwards
valve,16,26 the Carpentier-Edwards pericardial valve,27,28
and the low-pressure fixed Hancock II valve29,30 it is
approximately 65 years. In contrast, the cutoff point for
the Intact valve in this series would appear to be 40
years (P = .0005, Fig 6).
The effect of age on structural valve deterioration is
most closely related to the incidence of calcification in
glutaraldehyde-treated tissue. Thus factors that
decrease calcification should improve durability, par-
ticularly in younger patients. Combined with zero-
pressure fixation of the leaflets and pressure fixation of
the aortic root (“physiologic fixation”), such factors
should provide a superior tissue valve that can be used
with more confidence in younger patients.
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